Similarly, germline polymorphisms in the VEGF pathway have been linked to recurrence in non-advanced differentiated thyroid cancer, suggesting their potential to refine prognostic assessments and guide treatment decisions (55). This evidence concerns the gene VEGFA and thyroid gland carcinoma.